Dobutamine 300 mg was administered orally to both healthy volunteers and to patients with circulatory failure. After the 300 mg dose of dobutamine, subjects were found to have a higher concentration of the drug in their plasma than the effective levels of 37.5 (SD 2:9) nglml (n = 5) normally seen during intravenous infusion of the clinically effective (5 Ilglkglmin) dose. This increased concentration waned within 90 minutes. A clinical effect of dobutamine on the circulation was observed in both the healthy volunteers and the patients. An increase in the cardiac index of the patients continued longer than 90 minutes. An unidentified substance was noticed on chromatography measuring plasma dobutamine concentrations, which may have contributed to the increased cardiac index, although its chemical formula could not be determined. The results suggest that the oral administration of dobutamine may be expected to have a long-lasting and significant therapeutic effect on patients with chronic circulatory failure.
impaired circulation might be expected from the absorbed dobutamine or its metabolic breakdown products.
This study was designed to determine the effects of oral administration of dobutamine to healthy volunteers and to patients with persisting circulatory failure.
MATERIALS AND METHODS

Subjects and course of the study (a) Volunteers
Eight healthy volunteers of either sex, aged from 24 to 45 years and weighing from 60 to 70 kg, were examined. After their physical conditions, including arterial blood pressure, pulse rates and ECG findings were confirmed within the normal range, they were fasted for twelve hours prior to the experiment.
In the early morning, 300 mg of pure dobutamine crystalline powder from a commercially packaged vial for injection was wrapped in a wafer and given orally to each volunteer.
Before the administration of dobutamine, blood samples from peripheral veins were taken as a control to the experiment. After administration, samples were collected at 30-minute intervals for 240 minutes and volunteers were constantly monitored for vital signs and ECG during this time.
Five of the eight volunteers were re-examined on a later day with 30 minutes of intravenous infusion of 5 flglkglmin of dobutamine (the usual clinical dose) and monitored as in the oral dobutamine trials. Peripheral venous samples were collected also just prior to termination of infusion and their plasma dobutamine concentrations were estimated for comparison with results seen after oral administration.
(b) Patients in fCU
Five patients in our intensive care unit (lCU) were selected as subjects because their haemodynamic conditions were being monitored with Swan-Ganz catheters and they required catecholamine administration. Written informed consent was obtained from either the patients or the families of unconscious patients.
The study was approved by the Ethical Committee for Researches in the Surugadai Nihon University Hospital. Two of the five patients had persisting cardiac failure with a low cardiac index caused by acute myocardial infarction. three patients had severe septicaemia and were obtunded. The values of their haemodynamic parameters prior to the administration of dobutamine are presented in Table l .
Haemodynamic conditions during the evaluation of each patient were estimated by routine methods using a thermodilution pulmonary artery catheter connected to a pressure transducer (P-50, Gould Statham, CA, U.S.A.), and the averaged value of three cardiac output measurements was recorded. These results were recorded with a multichannel recorder (Type 362, NEC Sannei, Tokyo, Japan) with the ECG tracing. Both measured and derived parameters are shown in Table 1 . Mixed venous blood samples to measure plasma dobutamine concentration were collected from the catheter.
Dobutamine, 300 mg crystalline powder, was given orally, wrapped in a wafer, to each of the two cardiac patients. For the three unconscious patients, the dose was dissolved in 20 ml of physiological saline and administered via a gastric tube. After the administration, measurements of cardiac output and sampling of mixed venous blood with determinations of blood pressures were repeated at 30-minute intervals for 180 minutes.
Measurement of plasma dobutamine concentration
Each blood sample collected was centrifuged at 3,000 rpm for five minutes at a low temperature (ca.4°C), and plasma was obtained. The plasma was then stored at -80°C until the assays were performed. The chromatographic assay was in general performed within three months after the sample was coilected.
The extraction of dobutamine was carried out according to the aluminium adsorption method. 4 The plasma sample (500 J.LI) was transferred to a glass-stoppered tube containing 0.1 ml of 0.1 M ethylenediamine tetra-acetate, 200 ng of 3,4dihydroxyphenylpropionic acid (internal standard substance), 1.0 ml oftris-HCI buffer (pH 8.6) and activated aluminium oxide. The tube was shaken on a reciprocal shaker for five minutes. After a brief centrifugation, the aqueous layer was discarded and the aluminium oxide was washed three times with distilled water.
Finally, to the tube was added 0.2 ml O.lN HCI and shaken for 30 seconds for extracting dobutamine. The HCllayer was injected into a high-performance liquid chromatographic system.
The chromatographic system consisted of an HPLC system (Model 510, Waters, Milford, M.A., U.S.A.), an Ultrasphere-ODS reversed phase column (average particle size, 5 J.Lm; 250 X 4.6 mm ID; Altex Scientific, Berkeley, CA., U.S.A.), a six-port injector (7125 Rheodyne, Berkeley, CA., U.S.A.), and a glassy carbon electrochemical detector (EC 100, Eicom, Kyoto, Japan). The detector potential was set at 600 m V versus an Ag/ AgCl reference electrode. The chromatographic mobile phase consisted of a 0.05M citrate buffer (pH 4.0) containing 2.5% tetrahydrofuran and 10% methanol. The flow rate was set at 1.4 mlImin.
Calculation
Body surface area was calculated from Dubois's formula of:
(height)0.725 X (weight)0.425 X 71.84 to obtain cardiac index, and other haemodynamic parameters were calculated by standard methods.
Analysis and evaluation of the results
Comparisons between groups were made using the paired and/or unpaired t test. Pvalues smaller than 0.05 were considered statistically significant.
RESULTS
Volunteers
No dobutamine was detected in the control plasma obtained from the eight volunteers.
Plasma dobutamine concentrations in each subject and their mean values and standard deviations after oral administration are shown in Figure 1 . The maximum concentration was reached at 30 minutes after the medication in five out of eight subjects, at 60 minutes in two other subjects, and at 90 minutes in one other. The mean levels of eight subjects in Figure 1 showed a curve with a peak of 48.9 (SD 35.3) ng/ml at 30 minutes after oral administration of dobutamine, and the mean concentration decreased rapidly.
In the five volunteers after 30 minutes of intravenous infusion of 5 J.Lg/kg/min of dobutamine, the mean plasma dobutamine concentration reached 37.5 (SD 2.9) ng/ml. After oral administration of dobutamine, the maximum plasma concentration levels of seven individual subjects and mean concentration rate of all eight subjects, at 30 to 60 minutes, exceeded the mean concentration of 37.5 ng/ml obtained by intravenous infusion. These increased concentrations decreased less than 10 ng/ml within 120 minutes in five subjects and at 180 minutes in one subject after oral administration. In the remaining two subjects, one of which had a maximum concentration exceeding 37.5 ng/ml and the other a maximum concentration lower than that level, their plasma dobutamine concentration decreased gradually over more than 180 minutes. The concentration level in all eight subjects reduced to less than the limit for detection at 240 minutes after oral administration. The time course of subjects' pulse rate and arterial pressure during the examination is shown in Figure 2 with mean rates and standard deviations of eight subjects. The heart rate showed a tendency to increase during the 30 minutes to 120 minutes and increased significantly (P < 0.01) at 60 and 90 minutes after medication, but tachycardia did not persist for more than 90 minutes following administration.
Detection of an unidentified substance in plasma
During measurements of plasma dobutamine concentrations in four volunteers at the beginning of the study, it was noticed Anaesthesia and Intensi"e Care, Vol. 16, No. ), August, 1988 that a peak which had not been detected in cases of intravenous administration was found on the chromatographic traces of all the plasma sampled after oral administration. Thus, a peak height for the unidentified substance was measured in the remaining four volunteers, as shown in Figure 3 .
Exact concentrations of this peak on chromatography could not be determined because the authentic standard of unknown substances by chromatography is not obtainable. To evaluate fluctuation of its concentration, the highest peak on chromatography in serial samples from each individual subject was fixed at 100% for the subject and the other peaks as relative concentrations compared with this highest peak level. As shown in Figure 4 , plasma concentrations of this unidentified substance showed a similar time course in the four subjects; its highest concentration was reached at 60 to 120 minutes after dobutamine administration, followed by a slower reduction than that of plasma dobutamine, as shown in Figure 1 .
Patients in fCU
The control haemodynamic values obtained from each patient are shown in Table 1 , and their time course with averaged values in five patients after oral or intragastric dobutamine administration are shown in Table 2 with plasma dobutamine concentrations. Changes were observed in heart rate, cardiac index and total systemic vascular resistance. Heart rate, which had been 92 (SO 12)/min in controls, increased slightly but significantly during 30 minutes (P<O.OI) to 180 minutes (P<0.05) after dobutamine administration.
Mean cardiac index increased from 3.65 (SO 1.22) lImin/m 2 to 4.96 (SO 1.69) at 30 minutes and to 4.77 (SD 1.49) lIminlm 2 at 60 minutes respectively after dobutamine administration. This trend continued until 240 minutes following administration. On the other hand, the plasma dobutamine concentration which reached peak levels at 30 minutes after medication and was followed by prompt decrease to control levels.
taken at 240 minutes after dobutamine administration_ A peak which was noticed after oral administration in the plasma of four volunteers was found also on the chromatographic traces in plasma of the patients, and it was found also in the plasma In order to make clear the correlation between cardiac index and plasma concentration of dobutamine and the unknown substance, estimated value of cardiac index in each period was defined as per cent change from the control, and the time course of their averaged rates was shown on the graph in Figure 5 with that of plasma concentrations of dobutamine and the unknown substance. The cardiac index showed maximal increases at 30 minutes after dobutamine medication followed by a gradual reduction, although the plasma dobutamine concentration reached peak levels at 30 minutes post-medication but it reduced rapidly. In contrast, the unknown substance which was not detected before dobutamine administration reached mean levels of 78.4 (SD 30.5) % at 30 minutes and 85.1 (SD 14.8) % at 90 minutes after dobutamine, and their increased levels were maintained at 57.3 (SD 24.3) % of maximal levels, even at 240 minutes. From Figure 5 , it seems that the time course of cardiac index, particularly at 90 minutes after medication, correlated closely with that of plasma concentrations of the unknown substance rather than that of the plasma dobutamine concentration. The unknown substance's chemical formula has not yet been identified.
As shown in Table 2 , total systemic vascular resistance was reduced temporarily but definitely (P < 0.05) in correlation with an increase of the cardiac index. Consequently, mean arterial pressure did not change significantly. No remarkable changes were noted in other circulatory parameters. DISCUSSION It is believed that catecholamine preparations, including dobutamine, have been used only by continuous intravenous infusion because of their rapid breakdown after oral ingestion. If the pharmacological effect of dobutamine can be obtained by oral administration, however, it may be possible to expect clinical advantages of long-lasting, steady effectiveness and ease of administration. A few preliminary trials of oral administration have been reported with rats and humans,3,6 and this study intended to establish definitely whether dobutamine can be absorbed through the human digestive system and thus would be of potential use clinically.
The following results were obtained during this study:
1. When 300 mg of dobutamine was given orally, effective plasma concentration derived from intravenous infusion of routine clinical doses could be observed in seven of eight volunteers within 60 minutes.
2. Clinical evidence of the absorption of dobutamine was shown in both volunteers and patients by an increase in plasma dobutamine concentration. However, the heart rates in volunteers and the cardiac index or heart rates in patients showed a tendency toward a more lasting increase than that of plasma dobutamine.
3. A peak on the trace of chromatography to determine plasma dobutamine concentration was noticed as an unknown substance after oral administration in both volunteers and patients.
4. The substance may contribute to maintain increased cardiac indices after 90 minutes or more post-dobutamine, although its chemical formula is as yet not identified.
Several experimental researchers report that dobutamine is metabolised rapidly in the liver to inactive conjugates with glucuronic acid and to 3-0-methyldobutamine. 5 Because these metabolites have no positive inotropic action, it has been accepted that the cardiovascular effects obtained the infusion of dobutamine is caused by direct action to cardiac /31 receptors of dobutamine itself. The results of this study, however, suggest that an active chemical substance other than 3-0methyldobutamine may contribute to an improved cardiac index and heart rate after dobutamine administration via the oral route, particularly in the later stages when dobutamine concentrations in the plasma have already decreased.
This unknown substance was adsorbed to alumina during the extraction process and it reacted to 600 m V in chromatography ( Figure  3) . These characteristics indicate definitely that this substance has a catechol nucleus but is not 3-0-methyldobutamine, since none of the 3-methoxymetabolites react at 600 m V. From these chemical characteristics and its time course, in relation to its concentration after dobutamine, it is reasonable to assume that this substance is one of its metabolites, although its exact chemical formula could not be defined in this study, because no standard material for comparison could be obtained. It is possible, however, that this unknown substance may be one of the twenty materials which were listed by Tuttle et al. 1 as materials having catechol nuclei with inotropic action on cardiac function because of the correlation between improvement of the cardiac index in patients and its plasma concentration after dobutamine had returned to control levels.
It could not be determined whether this substance appears in the plasma only when dobutamine is administered via the oral or intragastric route, or may be found also during intravenous infusion. In this study, the substance could not be detected in the plasma of the five volunteers given dobutamine via intravenous infusion for 30 minutes at 5 Ilg/ Anaesthesia and Intensive Care. Vol. 16. No. 3. August. 1988 kg/min. This result does not indicate that the substance never appears in the plasma even when a dose greater than 5 Ilg/kg/min is used and infused over a longer duration than 30 minutes. It has been demonstrated that a part of the intravenously infused dobutamine is excreted into the intestinal tract through the liver and is reabsorbed into the circulation, the so-called liver-intestinal circulationY It is not assumed therefore that this substance is a specific metabolite which is produced only in case of administration through the digestive tract. In this study, it is reasonable that a small dose during a short-term intravenous administration of dobutamine might have resulted in failure of detection of this substance or it may have been present at levels below the detection threshold.
It is concluded that 300 mg of dobutamine through either an oral or intragastric administration might have a clinical effect in patients with circulatory failure. The results suggest that a metabolite of the administered dobutamine may contribute to the appearance of a long-lasting inotropic effect, although its chemical formula could not be identified.
